Bristol Myers Squibb (BMY) Cash & Equivalents (2009 - 2026)

Bristol Myers Squibb has disclosed Cash & Equivalents across 18 years of filings, most recently posting $9.6 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 11.96% year-over-year to $9.6 billion; the TTM figure through Mar 2026 stood at $9.6 billion (down 11.96% YoY), while the FY2025 annual figure was $10.2 billion, down 1.32% from the prior year.
• Cash & Equivalents slipped to $9.6 billion in Q1 2026, from $10.2 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for BMY reached as high as $15.7 billion in Q3 2025 and fell as low as $6.3 billion in Q2 2024.
• The 5-year median for Cash & Equivalents is $9.6 billion (2026), against an average of $10.0 billion.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 42.88% — and 2025, when it jumped 100.21%.
• A 5-year view of Cash & Equivalents shows it stood at $9.1 billion in 2022, then rose by 25.66% to $11.5 billion in 2023, then declined by 9.75% to $10.3 billion in 2024, then slipped by 1.32% to $10.2 billion in 2025, then declined by 6.22% to $9.6 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $9.6 billion, $10.2 billion, and $15.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.